We don’t write about funding sources for health and medical technology development as a rule, but we want to call out Intel’s investment organization’s recently announced financial backing for two disruptive healthcare startups. Medical Informatics and Reveal Biosciences join 12 other tech companies in which Intel Capital will invest a total of $117 million. Intel made the announcements at its annual Intel Capital Growth summit in Phoenix.
Houston-based Medical Informatics’ Sickbay platform aggregates and analyzes data from a wide range of medical devices. The software gathers data via remote monitoring and applies machine-learning for real-time predictive critical care analytics. Sickbay’s driving purpose is patient-centered care enabled by data-driven medicine. According to Medical Informatics, its FDA-cleared Sickbay platform unlocks otherwise underutilized information for predictive medicine, risk stratification, and more.
Reveal Biosciences also uses artificial intelligence to improve patient care, in this case starting with tissue samples. The San Diego-based company’s ImageDX software employs deep-learning to analyze tissue biology to assist with research and with actionable patient care data for diagnosis, prognostics, tumor detection, and more. ImageDX uses 3DHistech scanners for high-resolution whole slide imaging.
In addition to healthcare startup funding, Intel also announced investments in disruptive AI, communication, and manufacturing tech companies. Intel’s participation includes more than just money. According to Wendel Brooks, Intel senior vice president and president of Intel Capital, “Our investment is just the start of our work with each of them.”
